Novel Resistance Mechanisms Including L1196Q, P1094H, and R1248_D1249 Insertion in Three Patients With NSCLC After ALK Tyrosine Kinase Inhibitor Treatment

Authors:

Abstract
No abstract available
Funding Information
  • Taiho Pharmaceutical
  • Center for Information Technology
  • Chugai Pharmaceutical
  • Bristol-Myers Squibb
  • Clovis Oncology
  • Pfizer
  • Kissei
  • Astellas Pharma
  • Merck Sharp and Dohme United Kingdom
  • AbbVie
  • Dainippon Sumitomo Pharma
  • Takeda Pharmaceutical Company
  • Kyowa Kirin
  • Janssen Pharmaceutica
  • University of Tokyo
  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science (18K06594)
  • Novartis
  • Ministry of Education, Culture, Sports, Science and Technology
  • AstraZeneca

This publication has 12 references indexed in Scilit: